This article is more than 5 years old. Information may no longer be current.

Long-term treatment of myopic CNV with intravitreal anti-VEGF appears effective

Am J Ophthalmol. 2009;147(1):94-100.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal bevacizumab for treatment of choroidal neovascularization due to pathological myopia appears to be effective, according to a pilot study.

Over 1 year, Japanese researchers looked retrospectively at 63 eyes of 63 patients with myopic CNV who were given intravitreal treatment with Avastin (bevacizumab, Genentech).

Between one and six treatments of 1 mg of bevacizumab were given in the first 12 months, resulting in decreased size of myopic CNV (P < .01) and improved best corrected visual acuity (P < .01). In 25 eyes, BCVA increased more than three lines; in three eyes, BCVA decreased more than three lines; and in 35 eyes, BCVA was unchanged.

Active leakage was monitored by fluorescein angiography, which showed 30 eyes with ceased leakage, 28 eyes with diminished leakage and five eyes with no change.

"Although the current study lacked a control group, [intravitreal bevacizumab] seems to be an effective treatment for [myopic] CNV after a long-term," the study authors said.